Expert Opinion on Drug Safety

Immune function testing of human pharmaceuticals: regulatory overshoot?
pp. 1-5(5)
Authors: Jan Willem van der Laan; Henk van Loveren

Drug interactions with angiotensin receptor blockers
pp. 7-18(12)
Authors: Steffen Böhler; David Pittrow; Peter Bramlage; Wilhelm Kirch

Heroin-associated nephropathy
pp. 19-28(10)
Authors: Reinhard B Dettmeyer; Johanna Preuß; Heike Wollersen; Burkhard Madea

Cardiovascular complications of immunosuppressive agents in renal transplant recipients
pp. 29-44(16)
Authors: Ali J Olyaei; Angelo M deMattos; William M Bennett

Toxicity of the topoisomerase I inhibitors
pp. 45-53(9)
Author: Karen Seiter

Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?
pp. 55-68(14)
Authors: Jambur Ananth; Smita Kolli

Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy
pp. 69-73(5)
Author: Nuno Borges

Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects
pp. 75-89(15)
Authors: Paul J Harwood; Peter V Giannoudis

Drug-induced movement disorders in children and adolescents
pp. 91-102(12)
Author: Robert L Rodnitzky

Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules
pp. 103-128(26)
Author: Rashmi R Shah

Efficacy and safety of oral retinoids in psoriasis
pp. 129-138(10)
Authors: JoEllen Van Zander; Seth J Orlow

Angiotensin receptor blockers and drug–drug interactions
pp. 139-140(2)
Author: Domenic A Sica